Spineway (ALSPW) Q3 2024 TU earnings summary

Executive summary

• Nine-month 2024 revenue reached €9.1 million, up 21% year-over-year, reflecting strong organic growth.

• Q3 2024 revenue was €2.6 million, a 24% increase compared to Q3 2023, driven by new product sales.

Financial highlights

• Q1 2024 revenue: €3.07 million (+28% year-over-year).

• Q2 2024 revenue: €3.47 million (+14% year-over-year).

• Q3 2024 revenue: €2.58 million (+24% year-over-year).

• Nine-month revenue: €9.11 million (+21% year-over-year).

Outlook and guidance

• Continued rollout of new Distimp product ranges in Latin America expected to support further growth.

• Marketing initiatives and training in legacy markets anticipated to sustain revenue momentum.

• International registration program progressing, despite some administrative delays.